Format

Send to

Choose Destination
Arch Osteoporos. 2017 Dec;12(1):43. doi: 10.1007/s11657-017-0324-5. Epub 2017 Apr 19.

UK clinical guideline for the prevention and treatment of osteoporosis.

Author information

1
Department of Medicine, Cambridge Biomedical Campus, Cambridge, UK. jec1001@cam.ac.uk.
2
Crawley Fracture Liaison Service, Crawley, Sussex, UK.
3
MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK.
4
University Hospitals Birmingham NHS Foundation Trust, Centre for Endocrinology, Diabetes and Metabolism, University of Birmingham & Birmingham Health Partners, Birmingham, UK.
5
Musculoskeletal Research Unit, University of Bristol and Royal United Hospital NHS Foundation Trust, Bath, UK.
6
Metabolic Bone, Nuffield Orthopaedic Hospital, Oxford, UK.
7
Centre for Metabolic Diseases, University of Sheffield Medical School, Sheffield, UK.
8
Metabolic Bone, University of Sheffield, Sheffield, UK.
9
Department of Medicine, Cambridge Biomedical Campus, Cambridge, UK.
10
Emeritus Professor of Rheumatology, University of Aberdeen, Aberdeen, UK.
11
Metabolic Bone Disease, University of Manchester, Manchester, UK.
12
National Osteoporosis Society, Camerton, UK.

Abstract

INTRODUCTION:

In 2008, the UK National Osteoporosis Guideline Group (NOGG) produced a guideline on the prevention and treatment of osteoporosis, with an update in 2013. This paper presents a major update of the guideline, the scope of which is to review the assessment and management of osteoporosis and the prevention of fragility fractures in postmenopausal women and men age 50 years or over.

METHODS:

Where available, systematic reviews, meta-analyses and randomised controlled trials were used to provide the evidence base. Conclusions and recommendations were systematically graded according to the strength of the available evidence.

RESULTS:

Review of the evidence and recommendations are provided for the diagnosis of osteoporosis, fracture-risk assessment, lifestyle measures and pharmacological interventions, duration and monitoring of bisphosphonate therapy, glucocorticoid-induced osteoporosis, osteoporosis in men, postfracture care and intervention thresholds.

CONCLUSION:

The guideline, which has received accreditation from the National Institute of Health and Care Excellence (NICE), provides a comprehensive overview of the assessment and management of osteoporosis for all healthcare professionals who are involved in its management.

KEYWORDS:

Fracture; Guideline; NOGG; Osteoporosis

PMID:
28425085
PMCID:
PMC5397452
DOI:
10.1007/s11657-017-0324-5
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center